Mankind Pharma reported revenue from operations of Rs. 4,338 crore for the second quarter of FY27, representing 17.3% YoY growth. EBITDA margins improved by 210 basis points to 27.1%, indicating stronger operating performance during the period.
Exports rose 32.7% YoY to Rs. 681 crore, while domestic revenue, excluding consumer healthcare, grew 15.9%. The company also highlighted its acquisition of Armed Cell Therapeutics as a strategic step into next-generation CAR-T therapies, which could strengthen its research and development capabilities over time.
